½ÃÀ庸°í¼­
»óǰÄÚµå
1587155

¼¼°èÀÇ ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå : ¼­ºñ½ºº°, ´Ü°èº°, ½ÃÇèµðÀÚÀκ°, ÀûÀÀÁõº°, ½ºÆù¼­º° ¿¹Ãø(2025-2030³â)

Clinical Trial Support Services Market by Service (Administrative Staff, Clinical Trial Site Management, Data Management), Phase (Phase I, Phase II, Phase III), Study Design, Indication, Sponsor - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 187 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀåÀº 2023³â 239¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â 261¾ï 9,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµÇ¸ç º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 9.59%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 455¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º¿¡´Â ±ÔÁ¤ Áؼö, ȯÀÚ ¸ðÁý, ½ÃÇè ¸ð´ÏÅ͸µ, µ¥ÀÌÅÍ °ü¸®, ¹°·ù °ü¸® µî ÀÓ»ó½ÃÇè ¼öÇà¿¡ ÇʼöÀûÀÎ ±¤¹üÀ§ÇÑ ºÎ´ë ¼­ºñ½º°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ¼­ºñ½º´Â º¹ÀâÇÑ ±ÔÁ¦ »óȲ¿¡ ´ëÀÀÇϰí, À±¸® ±âÁØÀ» ÁؼöÇϸç, ÀǾàǰ °³¹ß ÇÁ·Î¼¼½º¿¡¼­ µ¥ÀÌÅÍ ¹«°á¼ºÀ» À¯ÁöÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. Á¦¾à ¿¬±¸ÀÇ ±Þ¼ºÀå°ú ¼¼°è ÀÓ»ó½ÃÇè Áõ°¡¿¡ µû¶ó Áö¿ø ¼­ºñ½ºÀÇ ¿ëµµ´Â Á¦¾à, »ý¸í °øÇÐ ¹× ÀÇ·á±â±â ¾÷°è Àü¹Ý¿¡ °ÉÃÄ Å©°Ô È®»êµÇ°í ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè¼¾ÅÍ, °³¹ß¾÷¹«¼öʱâ°ü(CRO), Çмú±â°üÀÌ ÀÌ·¯ÇÑ ¼­ºñ½ºÀÇ ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚ·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ ¼ºÀåÀº ÀÓ»ó½ÃÇè¼ö Áõ°¡, ¿¬±¸°³¹ßÀ» Áö¿øÇÏ´Â Á¤ºÎÀÇ À¯¸®ÇÑ ÀÌ´Ï¼ÅÆ¼ºê, ¸ÂÃãÇü ÀÇ·áÀÇ ÃâÇö, ½Å±Ô Ä¡·á¸¦ ÇÊ¿ä·Î ÇÏ´Â Áúº´ÀÇ ¸¸¿¬¿¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ºñÁî´Ï½º ±âȸ´Â µ¥ÀÌÅÍ ºÐ¼®À» À§ÇÑ AI, µ¥ÀÌÅÍ º¸¾ÈÀ» À§ÇÑ ºí·ÏüÀÎ, ºÐ»êÇü ÀÓ»ó½ÃÇèÀ» À§ÇÑ ¿ø°ÝÀÇ·á µî ÷´Ü±â¼úÀÇ Ã¤¿ë¿¡ ÀÖ¾î È¿À²¼º Çâ»ó°ú ŸÀÓ¶óÀÎ ´ÜÃàÀ» Á¦°øÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 239¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 261¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 455¾ï 4,000¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 9.59%

±×·¯³ª ÷´Ü±â¼ú¿¡ µû¸¥ °íºñ¿ë, ¼÷·Ã Àü¹®°¡ÀÇ ºÎÁ·, ¾ö°ÝÇÑ ±ÔÁ¦»óÀÇ ¿ä±¸ µî ¼ºÀåÀ» ÀúÇØÇÏ´Â °úÁ¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. µÇ¾î ÀÖ½À´Ï´Ù. ¿£ÅÍÇÁ¶óÀÌÁîÀÇ °æ¿ì °ß°íÇÑ µ¥ÀÌÅÍ °ü¸® ¼Ö·ç¼ÇÀ» °³¹ßÇϰí ÀΰøÁö´ÉÀ» Ȱ¿ëÇÑ Å×½ºÆ® µðÀÚÀΰú ȯÀÚ Âü¿©¸¦ °­È­ÇÏ´Â µ¥ ÁßÁ¡À» µÓ´Ï´Ù. Áß¿äÇÑ °ÍÀº ±â¾÷ÀÌ ÀÌ·¯ÇÑ º¹ÀâÇÑ »óȲÀ» ±Øº¹Çϱâ À§Çؼ­´Â ƯÈ÷ µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿Í ȯÀÚ º¸È£¿¡ ´ëÇÑ ±ÔÁ¦ »óȲÀÇ º¯È­¿¡ ¹Î°¨ÇÑ °ÍÀÌ Áß¿äÇÕ´Ï´Ù. ¹ÙÀÌ¿À Á¦¾à ±â¾÷ ²÷ÀÓ¾ø´Â Áøº¸¿Í Çù·ÂÀÌ Æ¯Â¡ÀÔ´Ï´Ù. ±ÔÁ¦ µ¿ÇâÀ» ¿¹ÃøÇÏ°í °³º°È­µÈ ½ÃÇè ¼³°è¿¡ ÁÖ·ÂÇÔÀ¸·Î½á ±â¾÷Àº ÀÚ»çÀÇ ¼­ºñ½º¸¦ ½ÃÀå ¼ö¿ä¿¡ µû¶ó ÀûÀÀ½Ãų ¼ö ÀÖ¾î Áö¼Ó °¡´ÉÇÑ ¼ºÀå°ú °æÀï·ÂÀ» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ : ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. Á¤¹ÐÈ­ ¹× »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñ ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¶ÇÇÑ ¼ÒºñÀÚ Çൿ ±×¸®°í ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ÀÓ»ó½ÃÇè¼ö Áõ°¡¿Í ÇÔ²² ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ »ó½Â
    • ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ Á¤ºÎÁ¶¼º±Ý
    • ¼öŹ¿¬±¸±â°ü Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÀÓ»ó½ÃÇè¿¡ °üÇÑ ¾ö°ÝÇÑ ±ÔÁ¦
  • ½ÃÀå ±âȸ
    • »êÇÐ ¿¬°è Áõ°¡
    • Á¦¾à, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ÀÇ ¿¬±¸°³¹ßºñ
  • ½ÃÀåÀÇ °úÁ¦
    • Àú¼Òµæ±¹°¡ÀÇ ÇÑÁ¤µÈ ÀÎÇÁ¶ó

Porter's Five Forces ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­ ¹× ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·«ºÐ¼® ¹× Ãßõ ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀåÀÇ Àü·«ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ´É·Â ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÎ¹®¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÎ¹®ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ µµ¿òÀÌ µÇ´Â Áß¿äÇÑ Áú¹®¿¡ ÀÀ´äÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¸¸¼ºÁúȯÀÇ ÀÌȯÀ²ÀÇ »ó½Â°ú ÀÓ»ó½ÃÇè¼ö Áõ°¡
      • ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ Á¤ºÎÀÇ º¸Á¶±Ý
      • À§Å¹¿¬±¸±â°ü Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • ÀÓ»ó½ÃÇè¿¡¼­ ¾ö°ÝÇÑ ±ÔÁ¦ Áؼö
    • ±âȸ
      • »êÇÐ Á¦ÈÞ È®´ë
      • Á¦¾à, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ÀÇ ¿¬±¸°³¹ßºñ
    • °úÁ¦
      • Àú¼Òµæ±¹°¡ÀÇ Áö¿ø ÀÎÇÁ¶ó ºÎÁ·
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå : ¼­ºñ½ºº°

  • °ü¸® ½ºÅÇ
  • ÀÓ»ó½ÃÇè½Ã¼³°ü¸®
    • ȯÀÚ ¸ðÁý ¹× µî·Ï ¼­ºñ½º
    • ȯÀÚ ¸ðÁý °ü¸®
    • ȯÀÚ À¯Áö
  • µ¥ÀÌÅÍ °ü¸®
  • ±â°ü½É»çÀ§¿øÈ¸

Á¦7Àå ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå : ÆäÀÌÁ

  • ÆäÀÌÁî I
  • ÆäÀÌÁî II
  • ÆäÀÌÁî III
  • ÆäÀÌÁî IV

Á¦8Àå ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå : ¿¬±¸ µðÀÚÀÎ

  • È®Àå ¾×¼¼½º
  • °³ÀÔÀû
  • °üÂûÀû

Á¦9Àå ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå : ÀûÀÀÁõº°

  • ÀÚ°¡¸é¿ª ¶Ç´Â ¿°Áõ
  • ½ÉÀåÇ÷°ü
  • ´ç´¢º´
  • Á¾¾çÇÐ

Á¦10Àå ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå : ½ºÆù¼­

  • ÀÇ·á±â±â
  • ÀǾàǰ ¹× ¹ÙÀÌ¿ÀÀǾàǰ

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÓ»ó½ÃÇè Áö¿ø ¼­ºñ½º ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Alcura
  • Brighter Health Network LLC
  • Charles River Laboratories International, Inc.
  • Eli Lilly and Company
  • Eurofins Scientific SE
  • ICON PLC
  • Insight Medical Genetics
  • IQVIA Holdings Inc.
  • Laboratory Corporation of America Holdings
  • MARKEN Ltd.
  • Parexel International
  • Pfizer Inc.
  • PPD Inc.
  • Quotient Sciences Ltd.
  • Syneos Health Inc.
  • WuXi AppTec
BJH 24.11.15

The Clinical Trial Support Services Market was valued at USD 23.98 billion in 2023, expected to reach USD 26.19 billion in 2024, and is projected to grow at a CAGR of 9.59%, to USD 45.54 billion by 2030.

Clinical Trial Support Services encompass a wide array of ancillary services crucial to the execution of clinical trials, including regulatory compliance, patient recruitment, trial monitoring, data management, and logistics management. These services are indispensable in addressing the complex regulatory landscape, ensuring adherence to ethical standards, and maintaining data integrity in drug development processes. With the burgeoning growth in pharmaceutical research and increasing clinical trials worldwide, the application of support services has expanded vastly across pharmaceutical, biotechnology, and medical device industries. Clinical trial centers, contract research organizations (CROs), and academic institutions emerge as principal end-users of these services. Market growth is propelled by an increasing number of clinical trials, favorable government initiatives supporting R&D, the advent of personalized medicine, and growing disease prevalence necessitating novel treatments. Key opportunities in the market lie in the adoption of advanced technologies such as AI for data analytics, blockchain for data security, and telehealth for decentralized trials, offering enhanced efficiency and reduced timelines.

KEY MARKET STATISTICS
Base Year [2023] USD 23.98 billion
Estimated Year [2024] USD 26.19 billion
Forecast Year [2030] USD 45.54 billion
CAGR (%) 9.59%

However, the market faces challenges such as high costs associated with advanced technologies, the shortage of skilled professionals, and stringent regulatory demands that can hinder growth. Limitations also include geographical disparities in trial regulations and patient recruitment challenges. For businesses aiming at innovation, a focus on developing robust data management solutions and leveraging AI to enhance trial design and patient engagement is promising. Investment in training and development to address the talent gap is crucial. As companies navigate this complex landscape, sensitivity to regulatory changes, especially concerning data privacy and patient protection, is critical. The nature of the market is highly competitive and fragmented, marked by continuous advancements and collaboration between service providers and biopharma companies. By anticipating regulatory trends and focusing on personalized trial designs, companies can better align their services with market demands, ensuring sustainable growth and competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Clinical Trial Support Services Market

The Clinical Trial Support Services Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases coupled with increasing number of clinical trials
    • Government grants for clinical trials
    • Increasing number of contract research organizations
  • Market Restraints
    • Stringent regulatory compliance for clinical trials
  • Market Opportunities
    • Rising industry-academia collaborations
    • R&D spending of pharmaceutical & biotechnology companies
  • Market Challenges
    • Limited supportive infrastructure in low income economies

Porter's Five Forces: A Strategic Tool for Navigating the Clinical Trial Support Services Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Clinical Trial Support Services Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Clinical Trial Support Services Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Clinical Trial Support Services Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Clinical Trial Support Services Market

A detailed market share analysis in the Clinical Trial Support Services Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Clinical Trial Support Services Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Clinical Trial Support Services Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Clinical Trial Support Services Market

A strategic analysis of the Clinical Trial Support Services Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Clinical Trial Support Services Market, highlighting leading vendors and their innovative profiles. These include Alcura, Brighter Health Network LLC, Charles River Laboratories International, Inc., Eli Lilly and Company, Eurofins Scientific SE, ICON PLC, Insight Medical Genetics, IQVIA Holdings Inc., Laboratory Corporation of America Holdings, MARKEN Ltd., Parexel International, Pfizer Inc., PPD Inc., Quotient Sciences Ltd., Syneos Health Inc., and WuXi AppTec.

Market Segmentation & Coverage

This research report categorizes the Clinical Trial Support Services Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Service, market is studied across Administrative Staff, Clinical Trial Site Management, Data Management, and Institutional Review Boards. The Clinical Trial Site Management is further studied across Patient Recruitment & Registry Services, Patient Recruitment Management, and Patient Retention.
  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Study Design, market is studied across Expanded Access, Interventional, and Observational.
  • Based on Indication, market is studied across Autoimmune or Inflammation, Cardiovascular, Diabetes, and Oncology.
  • Based on Sponsor, market is studied across Medical Devices and Pharmaceutical & Biopharmaceutical.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases coupled with increasing number of clinical trials
      • 5.1.1.2. Government grants for clinical trials
      • 5.1.1.3. Increasing number of contract research organizations
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory compliance for clinical trials
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising industry-academia collaborations
      • 5.1.3.2. R&D spending of pharmaceutical & biotechnology companies
    • 5.1.4. Challenges
      • 5.1.4.1. Limited supportive infrastructure in low income economies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Clinical Trial Support Services Market, by Service

  • 6.1. Introduction
  • 6.2. Administrative Staff
  • 6.3. Clinical Trial Site Management
    • 6.3.1. Patient Recruitment & Registry Services
    • 6.3.2. Patient Recruitment Management
    • 6.3.3. Patient Retention
  • 6.4. Data Management
  • 6.5. Institutional Review Boards

7. Clinical Trial Support Services Market, by Phase

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV

8. Clinical Trial Support Services Market, by Study Design

  • 8.1. Introduction
  • 8.2. Expanded Access
  • 8.3. Interventional
  • 8.4. Observational

9. Clinical Trial Support Services Market, by Indication

  • 9.1. Introduction
  • 9.2. Autoimmune or Inflammation
  • 9.3. Cardiovascular
  • 9.4. Diabetes
  • 9.5. Oncology

10. Clinical Trial Support Services Market, by Sponsor

  • 10.1. Introduction
  • 10.2. Medical Devices
  • 10.3. Pharmaceutical & Biopharmaceutical

11. Americas Clinical Trial Support Services Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Clinical Trial Support Services Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Clinical Trial Support Services Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alcura
  • 2. Brighter Health Network LLC
  • 3. Charles River Laboratories International, Inc.
  • 4. Eli Lilly and Company
  • 5. Eurofins Scientific SE
  • 6. ICON PLC
  • 7. Insight Medical Genetics
  • 8. IQVIA Holdings Inc.
  • 9. Laboratory Corporation of America Holdings
  • 10. MARKEN Ltd.
  • 11. Parexel International
  • 12. Pfizer Inc.
  • 13. PPD Inc.
  • 14. Quotient Sciences Ltd.
  • 15. Syneos Health Inc.
  • 16. WuXi AppTec
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦